The 36-month beta value for CYTK is also noteworthy at 0.69. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CYTK is 100.94M, and at present, short sellers hold a 13.11% of that float. The average trading volume of CYTK on April 18, 2024 was 2.16M shares.
CYTK) stock’s latest price update
The stock price of Cytokinetics Inc (NASDAQ: CYTK) has plunged by -1.55 when compared to previous closing price of 69.00, but the company has seen a -8.65% decline in its stock price over the last five trading sessions. Market Watch reported 2024-04-10 that A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
CYTK’s Market Performance
Cytokinetics Inc (CYTK) has seen a -8.65% fall in stock performance for the week, with a 6.56% gain in the past month and a -20.72% plunge in the past quarter. The volatility ratio for the week is 4.79%, and the volatility levels for the past 30 days are at 4.73% for CYTK. The simple moving average for the past 20 days is -3.78% for CYTK’s stock, with a 35.97% simple moving average for the past 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with UBS repeating the rating for CYTK by listing it as a “Neutral.” The predicted price for CYTK in the upcoming period, according to UBS is $92 based on the research report published on January 24, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $90, previously predicting the price at $60. The rating they have provided for CYTK stocks is “Equal-Weight” according to the report published on January 05th, 2024.
Goldman gave a rating of “Buy” to CYTK, setting the target price at $50 in the report published on November 09th of the previous year.
CYTK Trading at -5.62% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.39% of loss for the given period.
Volatility was left at 4.73%, however, over the last 30 days, the volatility rate increased by 4.79%, as shares surge +0.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.26% lower at present.
During the last 5 trading sessions, CYTK fell by -8.65%, which changed the moving average for the period of 200-days by +108.25% in comparison to the 20-day moving average, which settled at $70.61. In addition, Cytokinetics Inc saw -18.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 32,605 shares at the price of $74.31 back on Apr 09 ’24. After this action, Malik Fady Ibraham now owns 138,567 shares of Cytokinetics Inc, valued at $2,422,918 using the latest closing price.
Malik Fady Ibraham, the EVP Research & Development of Cytokinetics Inc, sale 32,604 shares at $67.56 during a trade that took place back on Mar 05 ’24, which means that Malik Fady Ibraham is holding 138,973 shares at $2,202,606 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -65.9 for the present operating margin
- -32.4 for the gross margin
The net margin for Cytokinetics Inc stands at -69.64. The total capital return value is set at -0.69.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 2.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at -1.64. The interest coverage ratio of the stock is -8.6.
Currently, EBITDA for the company is -484.31 million with net debt to EBITDA at -1.37. When we switch over and look at the enterprise to sales, we see a ratio of 1028.71. The receivables turnover for the company is 5.87for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.12.
Conclusion
In summary, Cytokinetics Inc (CYTK) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
